December is a natural moment to look back at what defined life science in 2025. Several major themes emerged that will shape the field into 2026 and beyond. Here’s what actually mattered this year.
AI in Biology Became Routine
AlphaFold 3 and the wave of AI structure prediction tools that followed made the conversation stop being “should we use AI” and start being “how do we integrate AI into our workflow.” In computational biology specifically, machine learning went from being a specialized skill to a practical necessity.
The AI impact was most visible at conferences. When we covered [ASHG 2025](link to ASHG post) in November, the through-line across the meeting was clear: AI-driven genomic analysis, variant interpretation aided by machine learning, and computational tools that assume AI integration from the start. Wet lab researchers are increasingly expected to understand what their bioinformatician is doing with machine learning, and bioinformaticians are finding that standard tools now incorporate AI as a default layer.
This isn’t about “AI replacing biologists.” It’s about AI raising the floor of what’s possible and what’s expected. The pace of analysis accelerated, the interpretation became more sophisticated, and the bottleneck moved from computation to experimental design and biological insight.
GLP-1 Drugs Reshaped the Conversation Around Metabolism
The continued expansion of GLP-1 receptor agonists beyond diabetes and obesity shaped both academic research and industry investment. This wasn’t a 2025 story in origin, but 2025 was the year the field shifted from “interesting new drug class” to “core mechanism for understanding metabolic disease and aging.”
The interest spans academia (mechanistic research into how these drugs work), clinical medicine (expanding indications in cardiology, nephrology, neurology), and industry (drug discovery programs building new molecules in the space). For researchers working on metabolic disease, aging, or translational pharmacology, this was the year the entire ecosystem tilted toward these mechanisms.
Single-Cell and Spatial Omics Became Standard Tools
Single-cell RNA-seq stopped being a specialty technique in 2025. It became routine. This shift happened quietly, driven by falling costs, more reliable kits, and better bioinformatic pipelines. Spatial transcriptomics is following the same trajectory, with multiple platforms competing on ease of use and sample throughput.
For wet lab researchers, this means the conversation is shifting from “should we do single-cell sequencing” to “which platform, what resolution, and how do we handle the data.” The field is absorbing these methods into standard practice.
Academic Research Faced Real Budget Pressure
The funding environment for U.S. academic research tightened noticeably through 2025. NIH budgets are under pressure, success rates remain low, and the competitive landscape is intense. For postdocs and PhD students, this has meant longer searches for positions and more discussion about alternatives to traditional academic career paths. We’ve covered this ongoing challenge throughout the year.
ctDNA and Liquid Biopsy Reached Clinical Maturity
Cell-free DNA approaches for cancer monitoring continued clinical validation in 2025. The science has matured from “interesting research question” to “clinical tool.” This shift is important because it changes the type of research being done, the equipment labs need, and the opportunities for scientists who understand molecular oncology and biomarker development.
What to Watch in 2026
As we head into 2026, watch for:
- AI-driven drug discovery will accelerate. The conversation at major conferences will shift from “AI is possible” to “how much of our pipeline uses AI?”
- Regulatory frameworks around AI in medicine will emerge. FDA and global regulators will release clearer guidance on validating AI-driven diagnostics and predictions.
- Metabolic disease research will remain a major investment area. GLP-1 mechanisms will spawn follow-on drug programs and a wave of mechanistic research.
- The cost of genomics will continue dropping, making whole-genome or even whole-genome sequencing routine in clinical and research settings.
The field is moving fast. The scientists who stay current on these trends and understand how to work within new technical landscapes will have the most opportunities.